Akebia Therapeutics (AKBA) to Release Earnings on Thursday

Key Points

• Akebia Therapeutics is set to release its Q2 2025 earnings report on August 7th, with analysts anticipating a loss of ($0.02) per share and revenue of $47.60 million.
• In its previous earnings report, Akebia exceeded expectations by reporting a profit of $0.03 per share and revenue of $57.34 million.
• Insider trading activity indicates that key executives have sold shares recently, with CFO Erik Ostrowski decreasing his holdings by 7.58% after selling 41,314 shares.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $47.60 million for the quarter.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.06. The firm had revenue of $57.34 million during the quarter, compared to analyst estimates of $44.88 million. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Akebia Therapeutics Trading Up 0.8%

Shares of NASDAQ AKBA traded up $0.03 during midday trading on Friday, reaching $3.72. The stock had a trading volume of 3,017,137 shares, compared to its average volume of 4,131,279. The firm has a market cap of $977.02 million, a price-to-earnings ratio of -17.71 and a beta of 0.88. Akebia Therapeutics has a twelve month low of $1.07 and a twelve month high of $4.08. The company has a debt-to-equity ratio of 1.89, a quick ratio of 2.02 and a current ratio of 2.23. The company's 50 day moving average price is $3.61 and its 200 day moving average price is $2.64.

Insider Transactions at Akebia Therapeutics

In related news, CFO Erik Ostrowski sold 41,314 shares of the firm's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $3.67, for a total value of $151,622.38. Following the transaction, the chief financial officer owned 503,586 shares of the company's stock, valued at approximately $1,848,160.62. This trade represents a 7.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Richard C. Malabre sold 15,000 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $4.01, for a total transaction of $60,150.00. Following the completion of the transaction, the chief accounting officer directly owned 266,914 shares in the company, valued at approximately $1,070,325.14. The trade was a 5.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,648 shares of company stock worth $258,841 in the last three months. Insiders own 3.00% of the company's stock.

Hedge Funds Weigh In On Akebia Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its position in shares of Akebia Therapeutics by 171.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,724,439 shares of the biopharmaceutical company's stock worth $5,231,000 after buying an additional 1,722,245 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Akebia Therapeutics by 13.1% during the 1st quarter. AQR Capital Management LLC now owns 176,961 shares of the biopharmaceutical company's stock worth $340,000 after buying an additional 20,499 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Akebia Therapeutics by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 137,897 shares of the biopharmaceutical company's stock worth $265,000 after buying an additional 11,517 shares in the last quarter. Finally, Baird Financial Group Inc. lifted its position in shares of Akebia Therapeutics by 23.0% during the 1st quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company's stock worth $41,000 after buying an additional 4,000 shares in the last quarter. Institutional investors own 33.92% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on AKBA shares. Leerink Partnrs upgraded Akebia Therapeutics to a "strong-buy" rating in a report on Monday, April 28th. HC Wainwright started coverage on Akebia Therapeutics in a report on Wednesday, June 4th. They set a "buy" rating and a $8.00 price target for the company. Wall Street Zen upgraded Akebia Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 3rd. Finally, Leerink Partners initiated coverage on Akebia Therapeutics in a report on Monday, April 28th. They set an "outperform" rating and a $7.00 price target for the company. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Akebia Therapeutics presently has an average rating of "Buy" and an average price target of $6.75.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.